BR112013010704B8 - Composição compreendendo s-[2-([[1-(2-etil-butil)-ciclohexil]-carbonil]amino)fenila]2-metilpropanotioato e croscarmelose de sódio - Google Patents
Composição compreendendo s-[2-([[1-(2-etil-butil)-ciclohexil]-carbonil]amino)fenila]2-metilpropanotioato e croscarmelose de sódioInfo
- Publication number
- BR112013010704B8 BR112013010704B8 BR112013010704A BR112013010704A BR112013010704B8 BR 112013010704 B8 BR112013010704 B8 BR 112013010704B8 BR 112013010704 A BR112013010704 A BR 112013010704A BR 112013010704 A BR112013010704 A BR 112013010704A BR 112013010704 B8 BR112013010704 B8 BR 112013010704B8
- Authority
- BR
- Brazil
- Prior art keywords
- methylpropanethioate
- cyclohexyl
- carbonyl
- phenyl
- amino
- Prior art date
Links
- 229920002785 Croscarmellose sodium Polymers 0.000 title abstract 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 title abstract 4
- 229960001681 croscarmellose sodium Drugs 0.000 title abstract 4
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 title abstract 4
- YZQLWPMZQVHJED-UHFFFAOYSA-N 2-methylpropanethioic acid S-[2-[[[1-(2-ethylbutyl)cyclohexyl]-oxomethyl]amino]phenyl] ester Chemical compound C=1C=CC=C(SC(=O)C(C)C)C=1NC(=O)C1(CC(CC)CC)CCCCC1 YZQLWPMZQVHJED-UHFFFAOYSA-N 0.000 title abstract 3
- 239000008187 granular material Substances 0.000 abstract 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 abstract 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 abstract 2
- 239000008108 microcrystalline cellulose Substances 0.000 abstract 2
- 229940016286 microcrystalline cellulose Drugs 0.000 abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 2
- FFAADXOKPZHULO-UHFFFAOYSA-N 2-methylpropanethioic s-acid Chemical compound CC(C)C(S)=O FFAADXOKPZHULO-UHFFFAOYSA-N 0.000 abstract 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 abstract 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 abstract 1
- 229960000913 crospovidone Drugs 0.000 abstract 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 abstract 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 abstract 1
- 238000005507 spraying Methods 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/265—Esters, e.g. nitroglycerine, selenocyanates of carbonic, thiocarbonic, or thiocarboxylic acids, e.g. thioacetic acid, xanthogenic acid, trithiocarbonic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Inorganic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
uma composição compreendendo s- [2- ( [ [1- (2-etilbutila) - ciclohexila] - carbonila] amino) fenila] 2-metilpropanotioato e croscarmelose de sódio. a presente invenção se refere a uma composição compreendendo: a) s-[{2-([{1-(2-etilbutila) -ciclohexila]- carbonila]amino) fenila] 2-metilpropanotioato e b) croscarmelose de sódio. a presente invenção se refere também a um processo para a preparação de uma composição que compreende as seguintes etapas: a) misturar e granular, s-[2-([[1-(2-etilbutila) -ciclohexila] - carbonila]amino) fenila] 2-metilpropanotioato, crospovidona micronizada, celulose micro cristalina, croscarmelose de sódio e hidroxipropil metilcelulose; b) pulverizar até 0,5% em peso de hidroxipropil metilcelulose em água ou em 10% a 30% de etanol em peso/70% a 90% de água em peso, em grânulos obtidos de acordo com a etapa a); c) secar os granulados; e d) misturar a celulose micro cristalina, dióxido de silicone coloidal e estearilfumarato de sódio com os granulados secos obtidos de acordo com a etapa c).
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP10190045.4 | 2010-11-04 | ||
| EP10190045 | 2010-11-04 | ||
| PCT/EP2011/069087 WO2012059447A1 (en) | 2010-11-04 | 2011-10-31 | A composition comprising s-[2-([[1-(2-ethylbutyl)-cyclohexyl]-carbonyl]amino)phenyl]2-methylpropanethioate and croscarmellose sodium |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| BR112013010704A2 BR112013010704A2 (pt) | 2016-08-09 |
| BR112013010704B1 BR112013010704B1 (pt) | 2021-06-29 |
| BR112013010704B8 true BR112013010704B8 (pt) | 2021-11-09 |
Family
ID=43759428
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112013010704A BR112013010704B8 (pt) | 2010-11-04 | 2011-10-31 | Composição compreendendo s-[2-([[1-(2-etil-butil)-ciclohexil]-carbonil]amino)fenila]2-metilpropanotioato e croscarmelose de sódio |
Country Status (24)
| Country | Link |
|---|---|
| US (1) | US9107836B2 (pt) |
| EP (1) | EP2635263B1 (pt) |
| JP (1) | JP5676005B2 (pt) |
| KR (1) | KR101579659B1 (pt) |
| CN (2) | CN105833283A (pt) |
| AR (1) | AR083693A1 (pt) |
| BR (1) | BR112013010704B8 (pt) |
| CA (1) | CA2815280C (pt) |
| CL (1) | CL2013001164A1 (pt) |
| CR (1) | CR20130181A (pt) |
| EA (1) | EA025649B1 (pt) |
| EC (1) | ECSP13012603A (pt) |
| ES (1) | ES2553279T3 (pt) |
| IL (1) | IL225780B (pt) |
| MA (1) | MA34643B1 (pt) |
| MX (1) | MX345650B (pt) |
| MY (1) | MY164729A (pt) |
| NZ (1) | NZ609529A (pt) |
| PE (1) | PE20140018A1 (pt) |
| SG (1) | SG190025A1 (pt) |
| TW (1) | TWI507192B (pt) |
| UA (1) | UA110117C2 (pt) |
| WO (1) | WO2012059447A1 (pt) |
| ZA (1) | ZA201302954B (pt) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2596786B1 (en) | 2009-02-10 | 2019-11-27 | Amarin Pharmaceuticals Ireland Limited | Use of eicosapentaenoic acid ethyl ester for treating hypertriglyceridemia |
| KR102153557B1 (ko) | 2013-03-27 | 2020-09-09 | 에프. 호프만-라 로슈 아게 | 치료에 대한 반응성을 예측하기 위한 유전 마커 |
| JP5871984B2 (ja) * | 2013-04-15 | 2016-03-01 | 株式会社三和化学研究所 | オルメサルタンメドキソミルを含有する医薬組成物 |
| CA2924401A1 (en) | 2013-12-19 | 2015-06-25 | F. Hoffmann-La Roche Ag | Cetp modulator for use in the treatment of eye disease |
| EP3174995B1 (en) | 2014-07-30 | 2020-08-19 | F.Hoffmann-La Roche Ag | Genetic markers for predicting responsiveness to therapy with hdl-raising or hdl mimicking agent |
| CN104434913A (zh) * | 2014-12-20 | 2015-03-25 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹药物组合物及其制备方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2894445B2 (ja) | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Ｃｅｔｐ活性阻害剤として有効な化合物 |
| US7208465B2 (en) * | 2000-11-03 | 2007-04-24 | The Procter & Gamble Company | Methods and compositions for improved fragrancing of a surface |
| CA2509688A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Products Inc. | Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor |
| EP1603554A1 (en) | 2003-03-17 | 2005-12-14 | Japan Tobacco Inc. | Method for increasing the oral bioavailability of s-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate |
| US20040225018A1 (en) | 2003-03-17 | 2004-11-11 | Japan Tobacco Inc. | Pharmaceutical compositions of CETP inhibitors |
| WO2005011634A1 (en) * | 2003-08-04 | 2005-02-10 | Pfizer Products Inc. | Dosage forms providing controlled release of cholesteryl ester transfer protein inhibitors and immediate release of hmg-coa reductase inhibitors |
| JP2008528567A (ja) * | 2005-01-28 | 2008-07-31 | ファイザー・プロダクツ・インク | 速崩壊性の微孔性結合剤 |
| US7435849B2 (en) | 2005-10-31 | 2008-10-14 | Hoffmann-La Roche Inc. | Process for the production of acid chlorides |
| EP1935867A1 (en) | 2006-12-20 | 2008-06-25 | F. Hoffmann-La Roche Ag | Process for preparing 1-(2-ethyl-butyl)-cyclohexanecarboxylic acid |
| EP2373344B1 (en) * | 2008-12-08 | 2016-03-30 | F. Hoffmann-La Roche AG | Combined drug administration |
| US20110004011A1 (en) | 2009-07-01 | 2011-01-06 | Declan Costello | Novel process |
-
2011
- 2011-10-31 EA EA201390622A patent/EA025649B1/ru not_active IP Right Cessation
- 2011-10-31 CN CN201610309140.6A patent/CN105833283A/zh active Pending
- 2011-10-31 EP EP11776201.3A patent/EP2635263B1/en active Active
- 2011-10-31 KR KR1020137014214A patent/KR101579659B1/ko active IP Right Grant
- 2011-10-31 SG SG2013032123A patent/SG190025A1/en unknown
- 2011-10-31 WO PCT/EP2011/069087 patent/WO2012059447A1/en active Application Filing
- 2011-10-31 MY MYPI2013700710A patent/MY164729A/en unknown
- 2011-10-31 JP JP2013537093A patent/JP5676005B2/ja active Active
- 2011-10-31 BR BR112013010704A patent/BR112013010704B8/pt active IP Right Grant
- 2011-10-31 NZ NZ609529A patent/NZ609529A/en unknown
- 2011-10-31 CA CA2815280A patent/CA2815280C/en active Active
- 2011-10-31 CN CN2011800532370A patent/CN103200935A/zh active Pending
- 2011-10-31 UA UAA201306203A patent/UA110117C2/uk unknown
- 2011-10-31 MX MX2013004584A patent/MX345650B/es active IP Right Grant
- 2011-10-31 PE PE2013000910A patent/PE20140018A1/es not_active Application Discontinuation
- 2011-10-31 ES ES11776201.3T patent/ES2553279T3/es active Active
- 2011-11-03 AR ARP110104077A patent/AR083693A1/es unknown
- 2011-11-03 TW TW100140194A patent/TWI507192B/zh not_active IP Right Cessation
- 2011-11-03 US US13/288,082 patent/US9107836B2/en active Active
-
2013
- 2013-04-15 IL IL225780A patent/IL225780B/en active IP Right Grant
- 2013-04-23 ZA ZA2013/02954A patent/ZA201302954B/en unknown
- 2013-04-24 CR CR20130181A patent/CR20130181A/es unknown
- 2013-04-29 CL CL2013001164A patent/CL2013001164A1/es unknown
- 2013-05-03 EC ECSP13012603 patent/ECSP13012603A/es unknown
- 2013-05-03 MA MA35868A patent/MA34643B1/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112013010704B8 (pt) | Composição compreendendo s-[2-([[1-(2-etil-butil)-ciclohexil]-carbonil]amino)fenila]2-metilpropanotioato e croscarmelose de sódio | |
| GEP20156216B (en) | Heterocyclic compound and usage thereof | |
| BR112013000920A2 (pt) | compostos para a redução de produção de beta-amiloide | |
| DOP2016000285A (es) | Procedimiento para la preparación de 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridina-2-carboxamida, sus sales y su monohidrato | |
| BR112015010791A2 (pt) | moduladores de gpr40 de di-hidropirazol | |
| BR112012032244A2 (pt) | processo para preparar derivados de antranilamida com tetrazole-substituído e polimorfos cristalinos novos e derivados destes | |
| BR112012007979A2 (pt) | moduladores de gpr40 de pirrolidina | |
| BRPI0809842B8 (pt) | processo para a obtenção de linhagens de células aviárias diploides contínuas, processo de replicação de um vírus em uma linhagem de células aviárias diploides contínuas e processo de produção de peptídeos e proteínas recombinantes | |
| BR112015010779A2 (pt) | moduladores de di-hidropirazol gpr40 | |
| MX2009003316A (es) | Derivados de pirazina-2-carboxamida como moduladores receptores de cb2. | |
| EA200970811A1 (ru) | Новые производные бензамида в качестве модуляторов фолликулостимулирующего гормона | |
| BR112015011031A2 (pt) | moduladores de grp40 de di-hidropirazol | |
| EP3330254A3 (en) | Method and process for preparation and production of deuterated omega-diphenylurea | |
| BR112014011526A2 (pt) | composições em pó de casca de ovo e métodos de produção de composições em pó de casca de ovo | |
| BR112013000254A2 (pt) | derivados heterocíclicos 1-fenil-substituídos e seu uso como moduladores do receptor de prostaglandina d2 | |
| CL2011001405A1 (es) | Procedimiento para la preparacion de n-[2-(7-metoxi-1-naftil)etil]acetamida, agometalina. | |
| AU2012245971A8 (en) | A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation | |
| MX362691B (es) | Proceso para preparar cloruros de 4-[[(benzoil)amino]sulfonil]benz oílo y preparación de acilsulfamoilbenzamidas. | |
| BR112012014333A2 (pt) | Dispositivo de abertura, produto intermediário para formar um dispositivo de abertura, método para fabricação de um dispositivo de abertura, e, recipiente de embalagem | |
| ECSP12012207A (es) | Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida | |
| MX2013006031A (es) | Formulacion liposomal de dalcetrapib. | |
| EA201301136A2 (ru) | Новый способ синтеза (2e)-3-(3,4-диметоксифенил)проп-2-еннитрила, применение в синтезе ивабрадина и его фармацевтически приемлемых кислотно-аддитивных солей | |
| BR112012008332A2 (pt) | processo para preparação de cinacalcet | |
| EA201400473A1 (ru) | Способ синтеза 3,4-диметоксибицикло[4.2.0]окта-1,3,5-триен-7-карбонитрила и применение для синтеза ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой | |
| UA117900C2 (uk) | Спосіб синтезу 3-(2-бром-4,5-диметоксифеніл)пропаннітрилу та застосування в синтезі івабрадину та його адитивних солей з фармацевтично прийнятною кислотою |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] | ||
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] |
Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI |
|
| B06T | Formal requirements before examination [chapter 6.20 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 31/10/2011, OBSERVADAS AS CONDICOES LEGAIS. |
|
| B16C | Correction of notification of the grant [chapter 16.3 patent gazette] |
Free format text: REFERENTE AO DESPACHO 16.1 PUBLICADO NA RPI 2634, QUANTO AO ENDERECO DO TITULAR |